Trials / Unknown
UnknownNCT06169553
The Injection-Related InfectionS (IRIS) Program
The IRIS Program: A Novel Pathway to Optimize Treatment of Injection-related Infections for People Who Inject Drugs in Hamilton, Ontario
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- McMaster University · Academic / Other
- Sex
- All
- Age
- 16 Years – 105 Years
- Healthy volunteers
- Not accepted
Summary
People who inject drugs are at risk of injection-related infections, like abscesses or infective endocarditis. The Injection-Related InfectionS (IRIS) program hopes to improve treatment for participants by providing a low-barrier, one-stop shop model for people who inject drugs who experience injection-related infections to access more holistic and compassionate care. IRIS is a non-randomized clinical trial, meaning that it offers a specific program to eligible patients. This program offers care for substance use and infectious disease with additional peer support and systems navigation, if interested. The investigators anticipate enrolling 80 participants in the intervention and will follow participants throughout the infection treatment period (estimated 6-12 weeks). The investigators will collect information at the time of enrolment, at the 6-month mark, and monthly via electronic medical chart review. The investigators will use an interrupted time series analysis to evaluate the impact of the intervention on rates of treatment completion, emergency department visits, hospitalizations, and death, before versus after the intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Holistic injection-related injection treatment | Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs. |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2025-09-01
- Completion
- 2025-12-01
- First posted
- 2023-12-13
- Last updated
- 2023-12-13
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT06169553. Inclusion in this directory is not an endorsement.